Bradley Foster & Sargent Inc. CT lessened its stake in shares of APi Group Corporation (NYSE:APG – Free Report) by 45.0% during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 56,721 shares of the company’s stock after selling 46,352 shares during the period. Bradley Foster & Sargent Inc. CT’s holdings in APi Group were worth $2,298,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also bought and sold shares of the stock. Rathbones Group PLC raised its stake in APi Group by 215.7% during the 4th quarter. Rathbones Group PLC now owns 211,909 shares of the company’s stock worth $8,108,000 after buying an additional 144,789 shares during the period. Allspring Global Investments Holdings LLC boosted its holdings in APi Group by 2.0% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 4,831,219 shares of the company’s stock worth $188,273,000 after acquiring an additional 92,816 shares in the last quarter. Newbridge Financial Services Group Inc. grew its stake in APi Group by 75.4% in the fourth quarter. Newbridge Financial Services Group Inc. now owns 68,108 shares of the company’s stock valued at $2,606,000 after acquiring an additional 29,270 shares during the period. Sumitomo Mitsui DS Asset Management Company Ltd acquired a new stake in APi Group in the fourth quarter valued at approximately $5,593,000. Finally, Hantz Financial Services Inc. increased its holdings in shares of APi Group by 628.7% during the fourth quarter. Hantz Financial Services Inc. now owns 174,019 shares of the company’s stock valued at $6,658,000 after acquiring an additional 150,139 shares in the last quarter. 86.62% of the stock is owned by institutional investors.
APi Group Stock Performance Shares of APG stock opened at $39.58 on Monday. The firm has a 50-day moving average of $41.55 and a 200-day moving average of $42.78. The company has a market cap of $17.15 billion, a P/E ratio of -55.74, a P/E/G ratio of 2.31 and a beta of 1.60. The company has a debt-to-equity ratio of 0.79, a current ratio of 1.44 and a quick ratio of 1.36. APi Group Corporation has a one year low of $33.40 and a one year high of $49.99.
APi Group (NYSE:APG – Get Free Report) last posted its earnings results on Thursday, April 30th. The company reported $0.32 EPS for the quarter, topping the consensus estimate of $0.30 by $0.02. The firm had revenue of $1.98 billion for the quarter, compared to analysts’ expectations of $1.92 billion. APi Group had a net margin of 3.85% and a return on equity of 37.63%. The company’s quarterly revenue was up 15.3% compared to the same quarter last year. During the same quarter last year, the firm earned $0.37 EPS. Equities research analysts forecast that APi Group Corporation will post 1.71 EPS for the current fiscal year.
Insiders Place Their Bets In related news, Director Martin E. Franklin sold 2,000,000 shares of the stock in a transaction dated Thursday, June 11th. The shares were sold at an average price of $42.08, for a total transaction of $84,160,000.00. Following the completion of the transaction, the director owned 19,240,426 shares in the company, valued at approximately $809,637,126.08. This represents a 9.42% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Anthony E. Malkin sold 7,000 shares of the firm’s stock in a transaction dated Wednesday, June 17th. The stock was sold at an average price of $42.47, for a total transaction of $297,290.00. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 3,451,000 shares of company stock valued at $149,194,935. 18.70% of the stock is currently owned by company insiders.
Wall Street Analysts Forecast Growth APG has been the topic of a number of research reports. Robert W. Baird set a $52.00 target price on APi Group in a research report on Friday, May 1st. Citigroup reissued a “buy” rating and issued a $53.00 price target (up from $52.00) on shares of APi Group in a research report on Friday, May 1st. Wall Street Zen upgraded shares of APi Group from a “hold” rating to a “buy” rating in a research note on Saturday, May 2nd. Weiss Ratings downgraded shares of APi Group from a “hold (c)” rating to a “hold (c-)” rating in a report on Thursday, June 11th. Finally, Truist Financial set a $55.00 price objective on shares of APi Group and gave the company a “buy” rating in a research note on Friday, May 1st. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $53.17.
Read Our Latest Report on APG
APi Group Profile (Free Report)
APi Group Corp. is a global specialty contractor that provides fire protection, security, mechanical insulation and energy services to commercial, industrial and institutional clients. Headquartered in New Brighton, Minnesota, the company designs, installs, inspects, tests, maintains and repairs a wide range of safety and infrastructure systems. Through its network of operating subsidiaries, APi Group delivers end-to-end solutions for new construction, facility renovations and ongoing maintenance requirements.
Its service portfolio spans life safety and industrial services—such as fire suppression systems, fire alarms and emergency lighting—and specialized offerings including technical insulation, access solutions, passive fire protection and energy efficiency upgrades.
Featured Articles Five stocks we like better than APi Group RTX and Lockheed Earnings: Can Strong Guidance Reset the Defense Trade? These 4 Earnings Reports Expose the Market’s Growing Economic Divide Broadcom May Be the Biggest Winner From Alphabet’s Earnings Volatility Is Back and These 3 Market Tollbooths Are Best Positioned to Profit Want to see what other hedge funds are holding APG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for APi Group Corporation (NYSE:APG – Free Report).
Receive News & Ratings for APi Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for APi Group and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINEEntropy Technologies LP Has $2.69 Million Stock Holdings in The Ensign Group, Inc. $ENSG
NEXT HEADLINE »Entropy Technologies LP Acquires 5,979 Shares of Chemed Corporation $CHE
NEW BRIGHTON, Minn.--(BUSINESS WIRE)--APi Group Corporation (NYSE: APG) (“APi”) announced that it will release its second quarter 2026 financial results before the market opens on Thursday, July 30, 2026. Second Quarter Earnings Conference Call: APi will host a webcast and conference call to discuss its financial results at 8:30 a.m. ET on Thursday, July 30, 2026. Participants on the call will include Russell A. Becker, President and Chief Executive Officer, and David Jackola, EVP and Chief Fin.
NEW BRIGHTON, Minn.--(BUSINESS WIRE)--APi Group Corporation (NYSE: APG) ("APi" or the "Company") announced that on July 1, 2026, it closed the acquisition of WTech Fire Group ("WTech"), a leading provider of fire sprinkler, suppression and detection solutions across Europe. The acquisition, previously announced on April 17, 2026, adds highly complementary fire sprinkler and suppression capabilities to APi's international business. WTech is expected to contribute approximately $175 million in an.
APi Group Corporation (NYSE: APG) ("APi" or the "Company") announced that on July 1, 2026, it closed the acquisition of WTech Fire Group ("WTech"), a leading p
APi Group demonstrates strong growth momentum through double-digit organic growth and strategic M&A, notably acquiring Wtech Fire Group and Onyx-Fire Protection Service. APi Group raised full-year sales guidance twice post-acquisitions, now targeting $8.575–$8.775 billion revenue and $1.165–$1.225 billion adjusted EBITDA. Valuation has become more attractive, with shares down from April highs and forward P/E multiples compressing to around 20x on improved earnings outlook.
ROCKVILLE, Md. and SUZHOU, China, April 21, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, today announced that six abstracts from clinical studies of three key drug candidates have been selected for presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held in person at McCormick Place in Chicago, IL, and online, May 29 – June 2, 2026. With three abstracts selected for rapid oral presentations and three abstracts selected for poster presentations, these data highlight the global innovation and clinical value of Ascentage Pharma's portfolio, inclusive of Olverembatinib (HQP1351), the first third-generation BCR-ABL inhibitor approved in China; Lisaftoclax (APG-2575), the first approved China-developed Bcl-2 selective inhibitor; and Alrizomadlin (APG-115), an MDM2-p53 inhibitor.
NEW BRIGHTON, Minn.--(BUSINESS WIRE)--APi Group Corporation (NYSE: APG) (“APi” or the “Company”) today announced that it has entered into a definitive agreement to acquire Onyx-Fire Protection Services Inc. (“Onyx-Fire”), an inspection-first provider of fire and life safety services in Canada, from funds managed by Blackstone Tactical Opportunities (“Blackstone”). The transaction is expected to close in the second quarter of 2026, subject to customary closing conditions, including receipt of re.
NEW BRIGHTON, Minn.--(BUSINESS WIRE)--APi Group Corporation (NYSE: APG) (“APi” or the “Company”) today reported its financial results for the three months ended March 31, 2026. Russ Becker, APi's President and Chief Executive Officer, stated: "We are off to a strong start in 2026, delivering 10% organic net revenue growth and expanding adjusted EBITDA margins by 70 basis points year over year, with strength across both our Safety Services and Specialty Services segments. At the same time, we co.
APi (APG - Free Report) came out with quarterly earnings of $0.32 per share, beating the Zacks Consensus Estimate of $0.3 per share. This compares to earnings of $0.25 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of +5.26%. A quarter ago, it was expected that this company would post earnings of $0.4 per share when it actually produced earnings of $0.44, delivering a surprise of +10%.
Over the last four quarters, the company has surpassed consensus EPS estimates four times.
APi, which belongs to the Zacks Business - Services industry, posted revenues of $1.98 billion for the quarter ended March 2026, surpassing the Zacks Consensus Estimate by 3.56%. This compares to year-ago revenues of $1.72 billion. The company has topped consensus revenue estimates four times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
APi shares have added about 27.2% since the beginning of the year versus the S&P 500's gain of 4.2%.
What's Next for APi?While APi has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for APi was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $0.44 on $2.16 billion in revenues for the coming quarter and $1.67 on $8.51 billion in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Business - Services is currently in the bottom 37% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Willdan Group (WLDN - Free Report) , another stock in the same industry, has yet to report results for the quarter ended March 2026. The results are expected to be released on May 7.
This energy efficiency and sustainability consultant is expected to post quarterly earnings of $0.81 per share in its upcoming report, which represents a year-over-year change of +28.6%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.
Willdan Group's revenues are expected to be $89.55 million, up 4.9% from the year-ago quarter.
Although the revenue and EPS for APi (APG) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
NEW BRIGHTON, Minn.--(BUSINESS WIRE)--APi Group Corporation (NYSE: APG) ("APi" or the "Company") today announced the launch of a $500 million senior unsecured notes offering (the "Notes"), subject to market and other customary conditions. The Notes will be senior unsecured obligations of APi Group DE, Inc. ("APi DE"), a wholly owned subsidiary of the Company, and will be fully and unconditionally guaranteed on a senior unsecured basis by the Company and certain of the Company's existing and fut.
NEW BRIGHTON, Minn.--(BUSINESS WIRE)--APi Group Corporation (NYSE: APG) ("APi" or the "Company") today announced the pricing of the previously announced private offering by APi Group DE, Inc. ("APi DE"), a wholly owned subsidiary of the Company, of $500 million in aggregate principal amount of 5.75% senior notes due 2034 (the "Notes") at an offering price of 100% of the principal amount thereof. The Notes will be senior unsecured obligations of APi DE and will be fully and unconditionally guaranteed on a senior unsecured basis by the Company and certain of the Company's existing and future foreign and domestic subsidiaries. The offering is expected to close on or before May 14, 2026, subject to the satisfaction of customary closing conditions. APi intends to use the net proceeds from this financing for funding of the recently signed and announced Onyx-Fire Protection Services Inc. and Wtech Fire Group acquisitions, as well as for general corporate purposes.
The Notes are being offered in a private offering solely to parties reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"), and to non-U.S. persons in accordance with Regulation S under the Securities Act. No assurance can be given that the offering of the Notes will be completed, or, if completed, as to the terms on which it will be completed. This release does not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.
Forward Looking Statements:
This press release may contain “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and in the U.S. Private Securities Litigation Reform Act of 1995. Readers are cautioned not to place undue reliance on these forward-looking statements, and any such forward-looking statements are qualified in their entirety by reference to the following cautionary statements. All forward-looking statements speak only as of the date of this news release and are based on current expectations and involve a number of assumptions, risks and uncertainties that could cause the actual results to differ materially from such forward-looking statements.
About APi:
APi is a global, market-leading business services provider of fire and life safety, security, elevator and escalator, and specialty services with a substantial recurring revenue base and over 500 locations worldwide. APi provides statutorily mandated and other contracted services to a strong base of long-standing customers across industries. APi has a winning leadership culture driven by entrepreneurial business leaders delivering innovative solutions for customers. More information can be found at www.apigroupinc.com.
NEW BRIGHTON, Minn.--(BUSINESS WIRE)--APi Group Corporation (NYSE: APG) ("APi" or the "Company") today announced the closing of two previously announced financing transactions: a private offering of $500 million in aggregate principal amount of 5.75% senior notes due 2034, and an amendment to the Company's existing credit agreement (the "Amendment"), which extends the maturity of the Company's Term Loan B facility to 2033 and upsizes and extends the Company's revolving credit facility to $1.0 b.
NEW BRIGHTON, Minn.--(BUSINESS WIRE)--APi Group Corporation (NYSE: APG) (“APi” or the “Company”) today announced that its senior leadership team will be participating in a fireside chat during the William Blair 46th Annual Growth Stock Conference on Wednesday, June 3rd at 10:40 a.m. CT. A live webcast link and archived replay will be available in the “Events” area on the Investor Relations page of APi's website at APi Group Investor Relations - Events. Interested parties should check the Compan.
May 26, 2026 09:00 ET | Source: TOI Management, LLC
CERRITOS, Calif., May 26, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (“TOI”) (NASDAQ: TOI), one of the largest value-based oncology groups in the United States, today announced that Yale D. Podnos, MD, MPH, FACS, Chief Medical Officer, will participate in a panel discussion at the APG Spring Conference on May 28, 2026, in San Diego. The session, "Engaging More Specialists in Value-Based Care," will bring together healthcare leaders to discuss the growing role of specialists in advancing value-based care.
"Specialists play a critical role in delivering high-quality, coordinated care while helping improve outcomes and reduce the total cost of care," said Dr. Podnos. "As oncology continues to evolve, value-based models create opportunities to enhance the patient experience, maximize quality of life and survival outcomes, and improve care quality and patient safety."
Dr. Podnos will share insights on oncology's role in improving outcomes, reducing costs, and advancing value-based care delivery.
About The Oncology Institute (www.theoncologyinstitute.com):
Founded in 2007, The Oncology Institute (NASDAQ: TOI) is advancing oncology by delivering highly specialized, value-based cancer care in the community setting. TOI offers cutting-edge, evidence-based cancer care to a population of approximately 1.9 million patients, including clinical trials, transfusions, and other care delivery models traditionally associated with the most advanced care delivery organizations. With over 180 employed and affiliate clinicians and over 100 clinics and affiliate locations of care across five states and growing, TOI is changing oncology for the better.
ROCKVILLE, Md. and SUZHOU, China, May 31, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel therapies to address unmet medical needs in cancer, today announced that the Company presented its first dataset of alrizomadlin (APG-115), an MDM2-p53 inhibitor from the Company’s apoptosis-targeted pipeline, as monotherapy or in combination with lisaftoclax (APG-2575) in pediatric patients with relapsed/metastatic rhabdomyosarcoma (RMS) or other soft-tissue sarcomas (STSs), in a rapid oral presentation at the 62nd American Society of Clinical Oncology (ASCO) Annual Meeting.
The ASCO Annual Meeting showcases cutting-edge research in clinical oncology and advanced cancer therapies and is the world’s largest gathering of the clinical oncology community. This year marks Ascentage Pharma’s ninth consecutive appearance at ASCO. A total of six studies involving three of the Company’s key assets were selected for presentation, including three rapid oral presentations.
The data presented demonstrated preliminary antitumor activity and a manageable tolerability profile of alrizomadlin in pediatric solid tumors. Results showed that alrizomadlin monotherapy demonstrated initial clinical benefit in pediatric rhabdomyosarcoma (RMS), with one pediatric patient achieving a complete response (CR). In combination with investigational selective Bcl-2 inhibitor lisaftoclax, encouraging antitumor activity was observed, with an objective response rate (ORR) of 23.5% among 17 response-evaluable patients, including one complete response in a patient with Ewing sarcoma and three partial responses (PRs). In terms of safety, alrizomadlin, either as monotherapy or in combination with lisaftoclax, demonstrated a manageable safety profile in pediatric patients with solid tumors.
Alrizomadlin is an orally administered, highly selective MDM2-p53 inhibitor independently developed by Ascentage Pharma. It is the first investigational agent of its class to enter clinical development in China and has global first-in-class potential. By blocking the MDM2-p53 protein-protein interaction, alrizomadlin restores the tumor suppressor activity of p53 and induces apoptosis in tumor cells. Recently, alrizomadlin was officially included by the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) in the Pilot Program for the Support of Anti-tumor Drugs R&D for Kids, also known as the “SPARK Plan,” for development in pediatric solid tumors including neuroblastoma, rhabdomyosarcoma, and Ewing sarcoma.
Professor Yizhuo Zhang, principal investigator of the study from the Department of Pediatric Oncology at Sun Yat-sen University Cancer Center, said: “Relapsed/refractory pediatric sarcomas are associated with extremely poor prognosis and substantial unmet medical needs. The data presented at the ASCO meeting demonstrated a favorable tolerability profile and promising anti-tumor effect for alrizomadlin both as monotherapy and in combination with lisaftoclax, with the complete response (CR) cases being particularly encouraging. As a key candidate included in the SPARK Plan, alrizomadlin has the potential to become a first-in-class therapy, address unmet medical needs, and bring new hope for long-term survival to pediatric patients.”
Professor Yi Zhang, investigator of the study from the Department of Pediatrics at Beijing Tongren Hospital, Capital Medical University, said: “Treatment options for pediatric solid tumors, especially advanced soft-tissue sarcomas, remain very limited. The clinical data generated by the alrizomadlin combination regimen are therefore particularly meaningful. This apoptosis pathway-targeting therapy demonstrated favorable tolerability and encouraging objective response rates, further supporting the therapeutic potential of dual-target combination approaches in refractory pediatric tumors and providing valuable direction for future precision drug development in pediatric oncology.”
Yifan Zhai, MD, Chief Medical Officer of Ascentage Pharma, said: “Pediatric solid tumors continue to represent an area of significant unmet medical need. The data presented at ASCO mark our first presentation of alrizomadlin clinical data in pediatric solid tumor patients and demonstrated encouraging preliminary clinical benefit and tolerability. Importantly, alrizomadlin has already been included by the CDE in the SPARK Plan for potential development in multiple pediatric solid tumors. The data presented provide initial clinical evidence supporting this development strategy. We will continue to advance the related clinical studies with the goal of bringing new treatment options to pediatric patients in urgent need.”
Key highlights from the study presented at the 2026 ASCO Annual Meeting are as follows:
Alrizomadlin (APG-115) alone or in combination with Lisaftoclax (APG-2575) for the treatment of pediatric patients with relapsed/metastatic rhabdomyosarcoma (RMS) or other soft-tissue sarcomas (STSs)
Abstract #: 10012
Presentation Type: Rapid Oral Presentation
Session Title: Pediatric Oncology II
First Author: Yizhuo Zhang, MD, Department of Pediatric Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine
Key Highlights:
Research Background: This multicenter clinical trial conducted in China evaluated the safety and preliminary efficacy of alrizomadlin (APG-115) as monotherapy or in combination with lisaftoclax in heavily pretreated pediatric patients with relapsed/metastatic RMS, Ewing sarcoma (EWS), neuroblastoma (NB), and other solid tumors.Efficacy Data: In the monotherapy arm, 1 patient with refractory RMS achieved CR. In the combination arm, among 17 response-evaluable pediatric patients with relapsed/refractory solid tumors, the ORR was 23.5%, including 1 CR in a patient with EWS, as well as PRs in 2 patients with RMS and 1 patient with NB. The disease control rate (DCR) was 70.6%.Safety Data: No dose-limiting toxicities (DLTs) were observed in either the monotherapy or combination arm. Adverse events were primarily gastrointestinal and hematologic, with few serious adverse events and no treatment-related deaths or discontinuations.Conclusion: The regimen demonstrated a manageable safety profile and preliminary antitumor activity in pediatric solid tumors, supporting further investigation. * Alrizomadlin is currently under investigation and has not yet been approved by the US FDA.
About Ascentage Pharma
Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company”) is a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer. The Company has built a rich pipeline of innovative drug products and candidates that include inhibitors targeting key proteins in the apoptotic pathway, such as Bcl-2 and MDM2-p53, next-generation kinase inhibitors, and protein degraders.
The Company’s first approved product, olverembatinib, is the first novel third-generation BCR-ABL1 inhibitor approved in China for the treatment of patients with CML in chronic phase (CML-CP) with T315I mutations, CML in accelerated phase (CML-AP) with T315I mutations, and CML-CP that is resistant or intolerant to first and second-generation TKIs. It is covered by the China National Reimbursement Drug List (NRDL). Ascentage Pharma is currently conducting an FDA- and EMA-cleared registrational Phase III trial, called POLARIS-2, of olverembatinib for CML, as well as an FDA- and EMA-cleared registrational Phase III trials for patients with newly diagnosed Ph+ ALL, called POLARIS-1, and SDH-deficient GIST patients, called POLARIS-3.
The Company’s second approved product, lisaftoclax, is a novel Bcl-2 inhibitor for the treatment of various hematologic malignancies. Lisaftoclax has been approved by China’s National Medical Products Administration (NMPA) for the treatment of adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who have previously received at least one systemic therapy including Bruton’s tyrosine kinase (BTK) inhibitors. The Company is currently conducting four global registrational Phase III trials: the FDA- and EMA- cleared GLORA study of lisaftoclax in combination with BTK inhibitors in patients with CLL/SLL previously treated with BTK inhibitors for more than 12 months with suboptimal response; the GLORA-2 study in patients with newly diagnosed CLL/SLL; the GLORA-3 study in newly diagnosed, elderly and unfit patients with AML; and the FDA- and EMA-cleared GLORA-4 study in patients with newly diagnosed higher risk MDS.
Leveraging its robust R&D capabilities, Ascentage Pharma has built a portfolio of global intellectual property rights and entered into global partnerships and other relationships with numerous leading biotechnology and pharmaceutical companies, such as Takeda, AstraZeneca, Merck, Pfizer, and Innovent, in addition to research and development relationships with leading research institutions, such as Dana-Farber Cancer Institute, Mayo Clinic, National Cancer Institute and the University of Michigan. For more information, visit https://ascentage.com/
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, contained in this press release may be forward-looking statements, including statements that express Ascentage Pharma’s opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results of operations or financial condition. These forward-looking statements are subject to a number of risks and uncertainties as discussed in Ascentage Pharma’s filings with the SEC, including those set forth in the sections titled “Risk factors” and “Cautionary note regarding forward-looking statements” in its Annual Report on Form 20-F for the year ended December 31, 2025, filed with the SEC on April 29, 2026, the sections headed “Forward-looking Statements” and “Risks Factors” in the prospectus of the Company for its Hong Kong initial public offering dated October 16, 2019, and other filings with the SEC and/or The Stock Exchange of Hong Kong Limited where the Company’s ordinary shares are listed it has made or it makes from time to time that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. The forward-looking statements contained in this presentation do not constitute profit forecast by the Company’s management.
As a result of these factors, you should not rely on these forward-looking statements as predictions of future events. The forward-looking statements contained in this press release are based on Ascentage Pharma’s current expectations and beliefs concerning future developments and their potential effects and speak only as of the date of such statements. Ascentage Pharma does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Contact Information
Investor Relations:
Stella Yang
Ascentage Pharma [email protected]
+1 (301) 792-6286
- Stationary Oil/Gas Quote Activity Accelerating Given Current Global Events-
ALGONA, IA / ACCESS Newswire / June 1, 2026 / American Power Group Corporation ("APG") (OTC PINK:APGI) the leading U.S. based dual fuel diesel engine conversion technology company announced today that it has received approximately $250,000+ of stationary dual fuel conversion orders from its network of stationary certified dealer/installers. APG's stationary/off-road dual fuel installation base has exceeded 1,500 installations since 2010 and surpassed an estimated 25 million cumulative run hour milestone in high-horsepower applications which attests to the reliability of APG's dual fuel solution.
Chuck Coppa, APG's CEO/CFO stated, "We are pleased to see a measurable increase in quotation activity by our stationary certified dealer/installer network over the past several months. Despite the recent dramatic rise in gas and diesel prices, oil/gas field service companies remain cautious and thoughtful in their efforts to re-establish drilling activities which is why APG's S4000's reputation for the high up-time and the lowest TCO in the dual fuel sector is so appealing."
Mr. Coppa added, "In addition to these recent stationary dual fuel conversion orders, we currently have an additional $2 million+ of outstanding customer quotes spread among several of our stationary dealer/installers and are working diligently to convert these quotes into actual orders. Displacing up to 65% of the diesel fuel with natural gas has an enormous impact on operating costs, emissions and of course carbon footprint for operators using our technology."
APG's S4000 dual fuel technology seamlessly introduces natural gas from renewable, fossil or treated field gas into the induction system of a diesel engine, displacing up to 65% of the diesel fuel. The S4000 system does not change any of the OEM diesel engine components, maintaining base engine temperature and pressure parameters of the OEM engine. In
Generator power ratings from 100kW to 12MW have been successfully converted to APG's dual fuel technology on a wide array of OEM diesel engine platforms including:
About American Power Group Corporation (www.americanpowergroupinc.com)
American Power Group's subsidiary, American Power Group Inc., ("APG"), provides cost-effective alternative fueling solutions for diesel engines to significantly reduce methane criteria pollutants and help accelerate a low-carbon future. APG's Dual Fuel conversion technology is a unique patented hardware and software solution that enables high-horsepower diesel engines to safely displace up to 65% of diesel fuel with natural gas. Engines equipped with APG's Dual Fuel technology can use renewable natural gas (RNG), compressed natural gas (CNG), liquefied natural gas (LNG), captured flare-stack methane and conditioned well-head gas resulting in lower cost, lower carbon, and lower criteria pollutant emissions. Additionally, APG's Dual Fuel conversion technology remains fully compatible with eligible biodiesel blends and renewable diesel fuels further reducing a diesel engine's carbon footprint and provide users with a proven regulatory compliant technology.
Caution Regarding Forward-Looking Statements and Opinions
The matters described herein contain forward-looking statements and opinions, including, but not limited to, statements relating to outstanding dual fuel conversion quotes for $2 million + and our ability to turn these quotes into actual orders. These forward-looking statements and opinions are neither promises nor guarantees but involve risks and uncertainties that may individually or mutually impact the matters herein, and cause actual results, events, and performance to differ materially from such forward-looking statements and opinions. These risk factors include, but are not limited to, the fact that we may not be able to convert the $2 million+ of quotes into actual orders, the fact our dual fuel conversion business has lost money in prior fiscal years and the risk that we may require additional financing to grow our business, the fact that we rely on third parties to manufacture, distribute and install our products, we may encounter difficulties or delays in developing or introducing new products and keeping them on the market, we may encounter lack of product demand and market acceptance for current and future products, we may encounter adverse events or economic conditions, we operate in a competitive market and may experience pricing and other competitive pressures, we are dependent on governmental regulations with respect to emissions, including whether EPA approval will be obtained for future products and additional applications, the risk that we may not be able to protect our intellectual property rights, factors affecting the Company's future income and resulting ability to utilize its NOLs, the fact that our stock is thinly traded and our stock price may be volatile, and the fact that the exercise of stock options and warrants will cause dilution to our shareholders. Readers are cautioned not to place undue reliance on these forward-looking statements and opinions, which speak only as of the date hereof. Except as required by law, the Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements and opinions that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
Investor Relations Contact:
Chuck Coppa, CEO/CFO
American Power Group Corporation
978-729-9183 [email protected]
NEW BRIGHTON, Minn.--(BUSINESS WIRE)--APi Group Corporation (NYSE: APG) (“APi” or the “Company”), a global, market-leading business services provider of safety and specialty services, today announced its debut on the 2026 Fortune 500 list, earning the No. 486 position. The annual ranking, published by Fortune magazine, recognizes the 500 largest U.S. corporations by total revenue for the prior fiscal year. APi Group earned its place on the list with $7.9 billion in 2025 revenue, reflecting a long history of consistent growth across its safety and specialty services platforms.
“Joining the Fortune 500 is a meaningful milestone for APi on our 100-year anniversary and is a direct reflection of the dedication of our 29,000 teammates around the world. It is a testament to the consistent execution of our strategy as we continue building a durable, services-led business for the long term,” said Russ Becker, President and Chief Executive Officer of APi Group.
APi Group's debut on the Fortune 500 reflects the strength of the Company's differentiated business model, which is anchored in statutorily mandated, inspection-driven services that generate a high-quality, recurring revenue base. Combined with a disciplined approach to both organic growth and value-enhancing M&A, this model has driven consistent performance and positions APi to continue compounding value for shareholders.
About APi:
APi is a global, market-leading business services provider of fire and life safety, security, elevator and escalator, and specialty services with a substantial recurring revenue base and over 500 locations worldwide. APi provides statutorily mandated and other contracted services to a strong base of long-standing customers across industries. APi has a winning leadership culture driven by entrepreneurial business leaders delivering innovative solutions for customers. In 2026, APi is proud to celebrate its 100-year anniversary and its debut on the Fortune 500. More information can be found at www.apigroup.com.
APi Group Corporation (NYSE: APG) (âAPiâ or the âCompanyâ), a global, market-leading business services provider of safety and specialty services, today
NEW BRIGHTON, Minn.--(BUSINESS WIRE)--APi Group Corporation (NYSE: APG) ("APi" or the "Company") today announced that on June 8, 2026, it closed the acquisition of Onyx-Fire Protection Services, Inc. ("Onyx-Fire"), a leading inspection-first provider of fire and life safety services in Canada. The acquisition, previously announced on April 23, 2026, strengthens APi's position as a premier provider of safety services focused on non-discretionary, regulatory-driven, recurring revenue. Onyx-Fire i.
On June 11, 2026, APi Group Corp (APG) shares rose 3.1% today, bringing the current price to $42.66. The stock has experienced a 52-week range of $31.75 to $49.
